Integrum AB Series B

Research Integrum AB Series B (INTEG-B) on Bullrun: market cap SEK 232.81M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is SEK 232.81M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025SEK 97.00M-SEK 29.89M-SEK 49.71M75.6%-1.4SEK 7.77MSEK 4.02MSEK 156.95M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-05SEK 232.81Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 SEK.

About Integrum AB Series B

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Integrum AB Series B's market cap?

Integrum AB Series B's market capitalization is SEK 232.81M.

What does Integrum AB Series B do?

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation.